IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 114 filers reported holding IMMUNOVANT INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,862,537 | +109.0% | 74,565 | +3.3% | 0.00% | +50.0% |
| Q2 2023 | $1,369,596 | +123176.0% | 72,198 | +0.8% | 0.00% | +100.0% |
| Q1 2023 | $1,111 | -10.4% | 71,648 | +2.6% | 0.00% | -50.0% |
| Q4 2022 | $1,240 | -99.6% | 69,842 | +12.0% | 0.00% | +100.0% |
| Q3 2022 | $348,000 | +53.3% | 62,382 | +7.2% | 0.00% | – |
| Q2 2022 | $227,000 | -9.6% | 58,175 | +28.0% | 0.00% | – |
| Q1 2022 | $251,000 | -35.3% | 45,464 | -0.1% | 0.00% | – |
| Q4 2021 | $388,000 | -3.2% | 45,489 | -1.3% | 0.00% | -100.0% |
| Q3 2021 | $401,000 | -14.1% | 46,090 | +4.3% | 0.00% | 0.0% |
| Q2 2021 | $467,000 | -30.6% | 44,210 | +5.4% | 0.00% | 0.0% |
| Q1 2021 | $673,000 | -66.7% | 41,958 | -4.0% | 0.00% | -66.7% |
| Q4 2020 | $2,019,000 | +52.0% | 43,713 | +15.8% | 0.00% | +50.0% |
| Q3 2020 | $1,328,000 | +138.0% | 37,750 | +64.8% | 0.00% | +100.0% |
| Q2 2020 | $558,000 | – | 22,901 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |